Evidence map›Paper›PMID 20931357›Full record

ArticleBiochemical genetics2011

Lack of association of the N-acetyltransferase NAT1*10 allele with prostate cancer incidence, grade, or stage among smokers in Finland.

LaCreis R Kidd, David W Hein, Karen Woodson, Philip R Taylor, Demetrius Albanes, Jarmo Virtamo, Joseph A Tangrea

Abstract read
In one paragraph

Article in Biochemical genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.International journal of clinical and experimental medicine · 2015
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

LaCreis R KiddDepartment of Pharmacology and Toxicology, James Graham Brown Cancer Center, University of Louisville Health Sciences Center, 505 S. Hancock St., Louisville, KY 40292, USA. lrkidd01@louisville.edu
David W Hein
Karen Woodson
Philip R Taylor
Demetrius Albanes
Jarmo Virtamo
Joseph A Tangrea
National Cancer Institute · USCenter for Cancer Research · USDivision of Cancer Epidemiology and GeneticsJames Graham Brown Foundation · USUniversity of Louisville · US

Funding

PHARMACOGENETICS OF DRUG &CARCINOGEN METABOLISMR01CA034627 · NCI · UNIVERSITY OF NORTH DAKOTA · PI HEIN, DAVID W · 1985 to 2009
$3.1M
A Pharmacogenetic approach to prostate cancer susceptibilityR03CA128028 · NCI · UNIVERSITY OF LOUISVILLE · PI KIDD, LA CREIS RENEE · 2007 to 2008
$148k
FOLLOW UP OF THE ALPHA TOCOPHEROL, BETA CAROTENE LUNGN01CN045035 · CN · NATIONAL PUBLIC HEALTH INSTITUTE · PI VIRTAMO, JARMO · 1994 to 1997
–
U S-FINLAND STUDIES OF NUTRITION AND CANCERN01CN045165 · CN · NATIONAL PUBLIC HEALTH INSTITUTE · PI HEINONEN, OLLI P · 1985 to 1996
–
NCI NIH HHS N01 CN045035NCI NIH HHS N01 CN045165NCI NIH HHS N01 CN45035NCI NIH HHS N01 CN45165NCI NIH HHS R01 CA034627NCI NIH HHS R03 CA128028
6 · The paper itself

Abstract

Genetic variations in xenobiotic metabolizing genes can influence susceptibility to many environmentally induced cancers. Inheritance of the N-acetyltransferase 1 allele (NAT1*10), linked with increased metabolic activation of pro-carcinogens, is associated with an increased susceptibility to many cancers in which cigarette- or meat-derived carcinogens have been implicated in their etiology. The role of NAT1*10 in prostate cancer is under studied. Although cigarette smoking is not considered a risk factor for prostate cancer, a recent review suggests it may play a role in disease progression. Consequently, we examined the association of NAT1*10 with prostate cancer risk, grade, and stage among 400 Finnish male smokers using a case-control study design. Following genotyping of 206 patients and 196 healthy controls, our results do not support the role of NAT1*10 in relation to prostate cancer risk (OR = 1.28; 95% CI, 0.66-2.47), aggressive disease (OR = 0.58; 95% CI, 0.13-2.67), or advanced disease (OR = 1.19; 95% CI, 0.49-2.91).

Indexed as

AgedAllelesArylamine N-AcetyltransferaseCase-Control StudiesFinlandGenotypeHumansIncidenceIsoenzymesMaleMiddle AgedNeoplasm StagingPolymorphism, GeneticProstatic NeoplasmsRisk FactorsSmokingArylamine N-AcetyltransferaseIsoenzymesN-acetyltransferase 1

Identifiers

PMID20931357
PMCPMC3155982
OpenAlexW2145540910

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.